Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
45.87 (1y: +23%)
Market Cap 12.94 B P/E(ttm) 18.20
Enterprise Value 15.33 B P/B 3.10
STJ- NYSE (USA)
St Jude Medical, Inc.
  • Currently 4/5
Business Predictability Rank: 4-Star
Back Testing Results:
Average gain of all 4-Star stocks: 9.8% per year.
% of Stocks that are in still loss if held for 10yrs: 8%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$45.87
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry		 vs
history
Cash to Debt 0.388
STJ's Cash to Debt is ranked lower than
51% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 1.80 vs. STJ: 0.388 )
STJ' s 10-Year Cash to Debt Range
Min: 0.09   Max: No Debt
Current: 0.39
Equity to Asset 0.442
STJ's Equity to Asset is ranked higher than
51% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 0.60 vs. STJ: 0.442 )
STJ' s 10-Year Equity to Asset Range
Min: 0.44   Max: 0.81
Current: 0.44
0.44
0.81
Interest Coverage 16.2
STJ's Interest Coverage is ranked higher than
67% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 9.60 vs. STJ: 16.2 )
STJ' s 10-Year Interest Coverage Range
Min: 8   Max: No Debt
Current: 16.2
F-Score: 5
Z-Score: 3.13
M-Score: -2.79
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry		 vs
history
Operating margin (%) 20.00
STJ's Operating margin (%) is ranked higher than
90% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. STJ: 20.00 )
STJ' s 10-Year Operating margin (%) Range
Min: 15   Max: 24.7
Current: 20
15
24.7
Net-margin (%) 13.7
STJ's Net-margin (%) is ranked higher than
88% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 2.50 vs. STJ: 13.7 )
STJ' s 10-Year Net-margin (%) Range
Min: 2.2   Max: 17.9
Current: 13.7
2.2
17.9
ROE (%) 18.4
STJ's ROE (%) is ranked higher than
94% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 3.80 vs. STJ: 18.4 )
STJ' s 10-Year ROE (%) Range
Min: 3   Max: 23.4
Current: 18.4
3
23.4
ROA (%) 8.1
STJ's ROA (%) is ranked higher than
85% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. STJ: 8.1 )
STJ' s 10-Year ROA (%) Range
Min: 1.6   Max: 14.2
Current: 8.1
1.6
14.2
ROC (Joel Greenblatt) (%) 43.40
STJ's ROC (Joel Greenblatt) (%) is ranked higher than
87% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 9.60 vs. STJ: 43.40 )
STJ' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 32.4   Max: 59.8
Current: 43.4
32.4
59.8
Revenue Growth (%) 6.5
STJ's Revenue Growth (%) is ranked higher than
85% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. STJ: 6.5 )
STJ' s 10-Year Revenue Growth (%) Range
Min: 6.5   Max: 15.4
Current: 6.5
6.5
15.4
EBITDA Growth (%) 3.4
STJ's EBITDA Growth (%) is ranked higher than
85% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. STJ: 3.4 )
STJ' s 10-Year EBITDA Growth (%) Range
Min: 3.4   Max: 16.6
Current: 3.4
3.4
16.6
EPS Growth (%) 1.4
STJ's EPS Growth (%) is ranked higher than
86% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. STJ: 1.4 )
STJ' s 10-Year EPS Growth (%) Range
Min: 1.4   Max: 79.3
Current: 1.4
1.4
79.3
» STJ's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

STJ Guru Trades in Q2 2012

David Dreman 446,657 sh (New)
Ray Dalio 173,436 sh (+1017.07%)
Joel Greenblatt 64,984 sh (+255.55%)
John Rogers 1,469,205 sh (+13.4%)
Jeremy Grantham 246,281 sh (+5.17%)
Bill Frels 1,822,930 sh (+2.88%)
Vanguard Health Care Fund 9,110,900 sh (+1.11%)
John Hussman 1,251,400 sh (+0.11%)
Andreas Halvorsen Sold Out
George Soros Sold Out
Mario Gabelli 68,516 sh (-1.87%)
James Barrow 362,890 sh (-10.02%)
Jim Simons 629,913 sh (-24.42%)
Pioneer Investments 930,926 sh (-58.84%)
Steven Cohen 3,387 sh (-82.34%)
Paul Tudor Jones 14,000 sh (-92.29%)
» More
Q3 2012

STJ Guru Trades in Q3 2012

Ken Fisher 34,075 sh (New)
Bill Frels 1,875,195 sh (+2.87%)
Vanguard Health Care Fund 9,110,900 sh (unchged)
John Hussman 1,251,400 sh (unchged)
Paul Tudor Jones Sold Out
Jeremy Grantham 240,900 sh (-2.18%)
John Rogers 1,425,780 sh (-2.96%)
James Barrow 349,860 sh (-3.59%)
Mario Gabelli 62,753 sh (-8.41%)
Joel Greenblatt 52,045 sh (-19.91%)
David Dreman 317,543 sh (-28.91%)
Jim Simons 302,213 sh (-52.02%)
Ray Dalio 58,856 sh (-66.06%)
Steven Cohen 843 sh (-75.11%)
Pioneer Investments 26,000 sh (-97.21%)
» More
Q4 2012

STJ Guru Trades in Q4 2012

Sarah Ketterer 562,800 sh (New)
Paul Tudor Jones 22,000 sh (New)
Ray Dalio 418,456 sh (+610.98%)
Ken Fisher 194,705 sh (+471.4%)
James Barrow 1,933,300 sh (+452.59%)
Steven Cohen 3,994 sh (+373.78%)
Joel Greenblatt 73,123 sh (+40.5%)
Mario Gabelli 69,673 sh (+11.03%)
Vanguard Health Care Fund 10,110,900 sh (+10.98%)
Bill Frels 1,886,510 sh (+0.6%)
Jeremy Grantham 235,863 sh (unchged)
Pioneer Investments Sold Out
Jim Simons Sold Out
John Rogers 1,349,601 sh (-5.34%)
John Hussman 1,044,800 sh (-16.51%)
David Dreman 144,614 sh (-54.46%)
» More
Q1 2013

STJ Guru Trades in Q1 2013

Ken Fisher 308,620 sh (+58.51%)
James Barrow 2,735,000 sh (+41.47%)
Steven Cohen 5,489 sh (+37.43%)
John Rogers 1,675,741 sh (+24.17%)
Joel Greenblatt 90,730 sh (+24.08%)
Mario Gabelli 81,106 sh (+16.41%)
Bill Frels 1,915,010 sh (+1.51%)
Jeremy Grantham 236,563 sh (+0.3%)
Paul Tudor Jones Sold Out
David Dreman 139,110 sh (-3.81%)
Ray Dalio 340,949 sh (-18.52%)
Sarah Ketterer 425,000 sh (-24.48%)
Vanguard Health Care Fund 7,500,400 sh (-25.82%)
John Hussman 4,900 sh (-99.53%)
» More
» Details

Insider Trades

Latest Guru Trades with STJ

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Hussman 2013-03-31 Reduce -99.53%0.99%$36.14 - $43.12 $ 45.6612%4900
Vanguard Health Care Fund 2013-03-31 Reduce -25.82%0.25%$36.14 - $43.12 $ 45.6612%7500400
James Barrow 2013-03-31 Add 41.47%0.06%$36.14 - $43.12 $ 45.6612%2735000
Joel Greenblatt 2013-03-31 Add 24.08%0.04%$36.14 - $43.12 $ 45.6612%90730
David Dreman 2012-12-31 Reduce -54.46%0.18%$31.37 - $43.69 $ 45.6622%144614
Ray Dalio 2012-12-31 Add 610.98%0.13%$31.37 - $43.69 $ 45.6622%418456
James Barrow 2012-12-31 Add 452.59%0.11%$31.37 - $43.69 $ 45.6622%1933300
Joel Greenblatt 2012-12-31 Add 40.5%0.04%$31.37 - $43.69 $ 45.6622%73123
Joel Greenblatt 2012-12-31 Add 40.5%0.04%$31.37 - $43.69 $ 45.6622%73123
David Dreman 2012-09-30 Reduce -28.91%0.12%$36.32 - $43.04 $ 45.6617%317543
Ray Dalio 2012-09-30 Reduce -66.06%0.07%$36.32 - $43.04 $ 45.6617%58856
David Dreman 2012-06-30 New Buy0.42%$35.19 - $43.75 $ 45.6618%446657
Joel Greenblatt 2012-06-30 Add 255.55%0.14%$35.19 - $43.75 $ 45.6618%64984
George Soros 2012-06-30 Sold Out 0.1%$35.19 - $43.75 $ 45.6618%0
Ray Dalio 2012-06-30 Add 1017.07%0.09%$35.19 - $43.75 $ 45.6618%173436
Premium More recent guru trades are included for Premium Members only!!
» Financial Charts

Peter Lynch Chart

Top Ranked Articles about St Jude Medical, Inc.

Sarah Ketterer Returns 24% in 2012 - Her Top Q4 Buys
February 25, 2013
Sarah Ketterer - Sarah Ketterer Returns 24% In 2012 - Her Top Q4 Buys
Sarah Ketterer is the CEO of Causeway Capital, which she co-founded in 2001. Causeway’s team manages $16.2 billion employing a quantitative, bottom-up approach with a macroeconomic overlay. Her International Value Fund has had strong performance recently, returning 8.20% since inception, and 24.23% over the last year. Read more...

Ratios

vs
industry		 vs
history
P/E(ttm) 18.20
STJ's P/E(ttm) is ranked higher than
73% of the 217 Companies
in the Global Medical Devices industry.

( Industry Median: 22.90 vs. STJ: 18.20 )
STJ' s 10-Year P/E(ttm) Range
Min: 12.71   Max: 78.55
Current: 18.2
12.71
78.55
P/B 3.10
STJ's P/B is ranked higher than
51% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. STJ: 3.10 )
STJ' s 10-Year P/B Range
Min: 2.13   Max: 8.61
Current: 3.1
2.13
8.61
P/S 2.60
STJ's P/S is ranked higher than
58% of the 333 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. STJ: 2.60 )
STJ' s 10-Year P/S Range
Min: 1.84   Max: 7.3
Current: 2.6
1.84
7.3
PFCF 14.00
STJ's PFCF is ranked higher than
79% of the 200 Companies
in the Global Medical Devices industry.

( Industry Median: 21.03 vs. STJ: 14.00 )
STJ' s 10-Year PFCF Range
Min: 9.89   Max: 60.36
Current: 14
9.89
60.36
EV-to-EBIT 13.9
STJ's EV-to-EBIT is ranked higher than
78% of the 220 Companies
in the Global Medical Devices industry.

( Industry Median: 18.50 vs. STJ: 13.9 )
STJ' s 10-Year EV-to-EBIT Range
Min: 10   Max: 34.3
Current: 13.9
10
34.3
PEG 1.3
STJ's PEG is ranked higher than
81% of the 84 Companies
in the Global Medical Devices industry.

( Industry Median: 2.22 vs. STJ: 1.3 )
STJ' s 10-Year PEG Range
Min: 0.72   Max: 3.29
Current: 1.3
0.72
3.29
Shiller P/E 20.1
STJ's Shiller P/E is ranked lower than
100% of the Companies
in the Global Medical Devices industry.

( Industry Median: vs. STJ: 20.1 )
STJ' s 10-Year Shiller P/E Range
Min: 14.36   Max: 71.79
Current: 20.1
14.36
71.79

Dividend & Buy Back

vs
industry		 vs
history
Dividend Yield 2.10
STJ's Dividend Yield is ranked higher than
90% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. STJ: 2.10 )
STJ' s 10-Year Dividend Yield Range
Min: 0.39   Max: 2.81
Current: 2.1
0.39
2.81
Dividend Payout 0.3785
STJ's Dividend Payout is ranked higher than
56% of the 110 Companies
in the Global Medical Devices industry.

( Industry Median: 0.30 vs. STJ: 0.3785 )
STJ' s 10-Year Dividend Payout Range
Min: 0.33   Max: 0.39
Current: 0.38
0.33
0.39
Yield on cost (5-Year) 2.10
STJ's Yield on cost (5-Year) is ranked higher than
89% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. STJ: 2.10 )
STJ' s 10-Year Yield on cost (5-Year) Range
Min: 0.39   Max: 2.81
Current: 2.1
0.39
2.81
Share Buyback Rate 2.2
STJ's Share Buyback Rate is ranked higher than
96% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. STJ: 2.2 )
STJ' s 10-Year Share Buyback Rate Range
Min: 2.2   Max: -1.9
Current: 2.2

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 9.9
STJ's Price/Net Current Asset Value is ranked higher than
72% of the 264 Companies
in the Global Medical Devices industry.

( Industry Median: 14.30 vs. STJ: 9.9 )
STJ' s 10-Year Price/Net Current Asset Value Range
Min: 8.4   Max: 24.4
Current: 9.9
8.4
24.4
Price/Tangible Book 39
STJ's Price/Tangible Book is ranked lower than
67% of the 272 Companies
in the Global Medical Devices industry.

( Industry Median: 3.90 vs. STJ: 39 )
STJ' s 10-Year Price/Tangible Book Range
Min: 6.3   Max: 34.4
Current: 39
6.3
34.4
Price/DCF (Projected) 1.1
STJ's Price/DCF (Projected) is ranked higher than
87% of the 134 Companies
in the Global Medical Devices industry.

( Industry Median: 1.70 vs. STJ: 1.1 )
STJ' s 10-Year Price/DCF (Projected) Range
Min: 0.9   Max: 2.7
Current: 1.1
0.9
2.7
Price/Median PS Value 0.6
STJ's Price/Median PS Value is ranked higher than
91% of the 284 Companies
in the Global Medical Devices industry.

( Industry Median: 0.90 vs. STJ: 0.6 )
STJ' s 10-Year Price/Median PS Value Range
Min: 0.5   Max: 1.7
Current: 0.6
0.5
1.7
Price/Peter Lynch Fair Value 1.5
STJ's Price/Peter Lynch Fair Value is ranked higher than
81% of the 53 Companies
in the Global Medical Devices industry.

( Industry Median: 1.90 vs. STJ: 1.5 )
STJ' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.9   Max: 2.6
Current: 1.5
0.9
2.6
Price/Graham Number 6.1
STJ's Price/Graham Number is ranked lower than
63% of the 195 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. STJ: 6.1 )
STJ' s 10-Year Price/Graham Number Range
Min: 2.7   Max: 7.8
Current: 6.1
2.7
7.8
Earnings Yield (Greenblatt) 7.20
STJ's Earnings Yield (Greenblatt) is ranked higher than
86% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 2.70 vs. STJ: 7.20 )
STJ' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.9   Max: 10
Current: 7.2
2.9
10
Forward Rate of Return (Yacktman) 16.46
STJ's Forward Rate of Return (Yacktman) is ranked higher than
96% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. STJ: 16.46 )
STJ' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 13   Max: 24.4
Current: 16.46
13
24.4

Business Description

St. Jude Medical, Inc. was incorporated in Minnesota in 1976. The Company develops, manufactures and distributes cardiovascular medical devices for the global cardiac rhythm management, cardiology and cardiac surgery and atrial fibrillation therapy areas and neurostimulation medical devices for the management of chronic pain. The Company's four operating segments are Cardiac Rhythm Management (CRM), Cardiovascular (CV), Atrial Fibrillation (AF) and Neuromodulation (NMD). Its CV operating segment focuses on both the cardiology and cardiac surgery therapy areas. Its main products in each operating segment are as follows: CRM - tachycardia implantable cardioverter defibrillator systems (ICDs) and bradycardia pacemaker systems (pacemakers); CV - vascular products, which include vascular closure products, pressure measurement guidewires, optical coherence tomography (OCT) imaging products, vascular plugs and other vascular accessories, and structural heart products, which include heart valve replacement and repair products and structural heart defect devices; AF - electrophysiology (EP) introducers and catheters, advanced cardiac mapping, navigation and recording systems and ablation systems; and NMD - neurostimulation products, which include spinal cord and deep brain stimulation devices. The Company markets and sells its products through both a direct sales force and independent distributors. The main geographic markets for its products are the United States, Europe, Japan and Asia Pacific. The Company's main competitors in this market are Medtronic, Inc. and Boston Scientific Corporation. These two competitors have invested substantial amounts in CRM research and development in a highly competitive market where rapid technological change is expected to continue, requiring the Company to invest heavily in R&D and effectively market its products. The Company's products, development activities and manufacturing processes are subject to extensive and rigorous regulation by the FDA pursuant to the Federal Food, Drug, and Cosmetic Act (FDCA), by comparable agencies in foreign countries and by other regulatory agencies and governing bodies.
Company Website
SEC Reports
Industry: Medical Devices
Compare:MDT, SYK, SMA, ZMH, EW
Traded in other countries:JUD.Germany
» More Articles for STJ

Headlines

Articles On GuruFocus.com
comment on STJ Apr 21 2013 
Sarah Ketterer Returns 24 Pct in 2012, Her Top Q4 Buys Feb 25 2013 
Why Cooperman and Price Are Betting on Boston Scientific’s Turnaround Dec 31 2012 
My Best Healthcare Stock Picks For 2013 | Last Year’s Picks Gained 31.55% Dec 04 2012 
Weekly CEO Sells Highlight: Entegris, Honeywell International, St Jude Medical and Wesco Internation Nov 05 2012 
Six Stocks Will Benefit If Mitt Romeny Wins Oct 08 2012 
comment on STJ Oct 07 2012 
Medtronic (MDT) Dividend Stock Analysis 2012 Oct 05 2012 
-12% in shares Outst Jul 18 2012 
Medtronic - A 'Must Own' Stock for 2012 Mar 07 2012 

More From Our Partners
FDA Nod for STJ's Ellipse & Assura - Analyst Blog Jun 13 2013 - ZACKS

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK